IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says
Executive Summary
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
You may also be interested in...
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.
Five Key Takeaways From Merck’s Q2 Earnings Release
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.
Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy
Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.